
Press Release

January 20, 2025

Sumitomo Pharma Co., Ltd.

**Sumitomo Pharma Announces Agreement on
Co-Promotion Collaboration Partner for Marketing of
PPLAT XEPLION® and XEPLION TRI® in Japan**

Sumitomo Pharma Co., Ltd. (hereinafter referred to as "Sumitomo Pharma") announced today that Sumitomo Pharma has concluded a co-promotion collaboration partner agreement (hereinafter referred to as "this agreement") with Johnson & Johnson (corporate name: Janssen Pharmaceutical K.K., headquarters: Chiyoda-ku, Tokyo, President: Shuhei Sekiguchi, hereinafter referred to as "Janssen") in Japan of the long-acting antipsychotic medication "XEPLION® Aqueous Suspension for IM Injection 25 mg Syringe", "50 mg Syringe", "75 mg Syringe", "100 mg Syringe" and "150 mg Syringe," which are indicated for "schizophrenia," as well as "XEPLION TRI® Aqueous Suspension for IM Injection 175 mg Syringe", "263 mg Syringe" and "350 mg Syringe" and "525 mg Syringe," which are indicated for "schizophrenia (only when appropriate treatment has been conducted with paliperidone every four weeks)" (generic name: paliperidone palmitate, collectively referred to as "the product"), currently marketed by Janssen Pharma in Japan.

1. Purposes of this agreement

Sumitomo Pharma is working on various measures to achieve early business recovery and renewed growth, aiming to transform fiscal 2024 into a turning point for the growth of the Sumitomo Pharma group.

Sumitomo Pharma focuses on the area of Psychiatry & Neurology as one of its priority disease areas for research and development, as well as focus areas in the Japanese market. Sumitomo Pharma has a strong marketing track record in the treatment of schizophrenia, including the sale of the atypical antipsychotic agent "Latuda®" and the antipsychotic agent "LONASEN® Tape," both created by Sumitomo Pharma.

With the addition of XEPLION® and XEPLION TRI® to Sumitomo Pharma's lineup in the Psychiatry & Neurology area, Sumitomo Pharma aims to contribute to the treatment of more patients with schizophrenia.

2. Details of this agreement

Sumitomo Pharma will conduct promotional activities in collaboration with Janssen from around February 2025. In addition, Sumitomo Pharma also plans to assume responsibility for local distribution in the future.

These products are long-lasting solutions administered at 4 or 12-week intervals for the treatment of schizophrenia.

3. Schedule of this agreement

Date of decision regarding the conclusion of this agreement	January 20, 2025
Date of the conclusion of this agreement	January 20, 2025

Date of the commencement of this agreement	January 20, 2025
--	------------------

4. Relationship with Janssen

There are no capital, personnel, or business relationships between Sumitomo Pharma and Janssen, and neither party is considered a related party.

5. Future outlook

The impact of this agreement on our consolidated financial results for the fiscal year 2024 is expected to be minimal.

Contact:

Corporate Communications, Global Finance

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp